Ballicules.com

Mitotane

LYSODREN

What it isAdrenolytic agent destroying adrenocortical cells; adrenocortical carcinoma and Cushing syndrome.

Why this oneIt is the only drug that is directly cytotoxic to the adrenal cortex.

What limits itIt causes adrenal insufficiency by design, so glucocorticoid replacement at higher-than-usual doses is mandatory. Neurotoxicity; it induces CYP3A4.

FDA-approved for

Off-label

FDA label

BOXED WARNING Adrenal crisis in the setting of shock, severe trauma, or infection may lead to death; withhold and administer exogenous steroids.
FDA dosingPopulationStartTargetMax
Adrenocortical carcinomaAdult2000–6000 mg/day in 3–4 divided dosesPlasma 14–20 mg/L

Renal Not recommended in severe impairment; in mild–moderate, monitor plasma levels frequently and adjust.

Hepatic Not recommended in severe impairment; in mild–moderate, monitor plasma levels frequently and adjust.

Titrate to plasma level 14–20 mg/L; neurotoxicity more likely >20 mg/L; levels may persist for weeks after stopping due to adipose accumulation.

Instructions

Cautions

Adverse reactions

Pregnancy Can cause fetal harm; preterm births and early pregnancy loss reported.

Lactation Excreted in human milk; do not breastfeed during treatment and while plasma levels remain detectable.

⚠ BOXED WARNING

Cost, est. cash$5,000–$30,000+/month or cycle

Generic entryNo US generic

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk3 / 4

Legacy pregnancy categoryD

Defining liabilityMyelosuppression and agent-specific hepatic, cardiac, pulmonary, neurologic or reproductive toxicity require oncology monitoring.

Mechanism of action: Mitotane ballicule

Mitotane ballicule: receptor binding, kinetics and half-life diagram

Open Mitotane in the interactive console ↗